Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction
Ended Project Grant Awarded Last action
- Award ID
- R01DA046102
- Recipient
-
Elysium Therapeutics, Inc. UEI CQ2LJLATAKH9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,876,933
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding
-
- $6,424,403.00 Federal
- $452,530.00 Non-federal
- Place of performance
- Cincinnati, OH 45227, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $452,530 | $0 | |
| Amendment | $452,530 | $452,530 | |
| Amendment | $267,754 | $0 | |
| Amendment | $2,409,790 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $2,841,799 | $0 |
Quick answers
Who received award R01DA046102?
R01DA046102 was awarded to Elysium Therapeutics, Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 15, 2018.
How much is award R01DA046102 worth?
$6,876,933 has been obligated on R01DA046102: $6,424,403 in federal funding and $452,530 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award